Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib

Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib

Abstract Background The aim of this study was to explore the relationship between follow-up imaging characteristics and overall survival (OS) in advanced hepatocellular carcinoma (HCC) patients under sorafenib treatment. Methods Associations between OS and objective response (OR) by mRECIST or early...

Full description

Bibliographic Details
Main Authors: Osman Öcal, Regina Schinner, Kerstin Schütte, Enrico N. de Toni, Christian Loewe, Otto van Delden, Vincent Vandecaveye, Bernhard Gebauer, Christoph J. Zech, Christian Sengel, Irene Bargellini, Antonio Gasbarrini, Bruno Sangro, Maciej Pech, Peter Malfertheiner, Jens Ricke, Max Seidensticker, for the SORAMIC study group
Format: Article
Language:English
Published: BMC 2022-01-01
Series:Cancer Imaging
Subjects:
Hepatocellular carcinoma
Sorafenib
mRECIST
Early tumor shrinkage
Objective response
Online Access:https://doi.org/10.1186/s40644-021-00439-x

Internet

https://doi.org/10.1186/s40644-021-00439-x

Similar Items